**Name of Journal: *World Journal of Stem Cells***

**Manuscript NO: 48901**

**Manuscript Type: EDITORIAL**

**Predicting differentiation potential of human pluripotent stem cells: Possibilities and challenges**

Liu LP *et al*. Prediction of hPSC differentiation

Li-Ping Liu, Yun-Wen Zheng

**Li-Ping Liu**, **Yun-Wen Zheng,** Institute of Regenerative Medicine, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang 212001, Jiangsu Province, China

**Li-Ping Liu**, **Yun-Wen Zheng,** University of Tsukuba Faculty of Medicine, Tsukuba, Ibaraki 305-8575, Japan

**Yun-Wen Zheng**, Yokohama City University School of Medicine, Yokohama 236-0004, Japan

**ORCID number:** Li-Ping Liu (0000-0003-4445-8403); Yun-Wen Zheng (0000-0001-9002-3190).

**Author contributions**: Liu LP and Zheng YW conceived the study and drafted the manuscript; both authors approved the final version of the article.

**Supported by** [National Natural Science Foundation of China](http://www.baidu.com/link?url=-Cr3BmBF8WCc2aq8apuz4ZmWzzF2RqKEYHLdk6JxJTTbxsAcBDtXIGS9AnYLowoRWBc7hhxTid7npzssji6lw-zGJW5LUXZXB-c2CjJnWofxcPTDwqcXyXNF6g6PXZjRKpR822BtW-icmsYXfbvZ-omvpdv9XrzcLbUxTL281na), No. 81770621; Ministry of Education, Culture, Sports, Science, and Technology of Japan, KAKENHI, No. 16K15604 and No. 18H02866; and Natural Science Foundation of Jiangsu Province, No. BK20180281.

**Conflict-of-interest statement**: The authors have no conflict of interest to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author**: **Yun-Wen Zheng, PhD, Associate Professor,** University of Tsukuba Faculty of Medicine, Tennodai 1-1-1, Tsukuba, Ibaraki 305-8575, Japan. ywzheng@md.tsukuba.ac.jp

**Received:** May 7, 2019

**Peer-review started:** May 10, 2019

**First decision:** June 5, 2019

**Revised:** June 12, 2019

**Accepted:** June 20, 2019

**Article in press:** June 20, 2019

**Published online:** July 26, 2019

**Abstract**

The capability of human pluripotent stem cell (hPSC) lines to propagate indefinitely and differentiate into derivatives of three embryonic germ layers makes these cells be powerful tools for basic scientific research and promising agents for translational medicine. However, variations in differentiation tendency and efficiency as well as pluripotency maintenance necessitate the selection of hPSC lines for the intended applications to save time and cost. To screen the qualified cell lines and exclude problematic cell lines, their pluripotency must be confirmed initially by traditional methods such as teratoma formation or by high-throughput gene expression profiling assay. Additionally, their differentiation potential, particularly the lineage-specific differentiation propensities of hPSC lines, should be predicted in an early stage. As a complement to the teratoma assay, RNA sequencing data provide a quantitative estimate of the differentiation ability of hPSCs *in vivo*. Moreover, multiple scorecards have been developed based on selected gene sets for predicting the differentiation potential into three germ layers or the desired cell type many days before terminal differentiation. For clinical application of hPSCs, the malignant potential of the cells must also be evaluated. A combination of histologic examination of teratoma with quantitation of gene expression data derived from teratoma tissue provides safety-related predictive information by detecting immature teratomas, malignancy marker expression, and other parameters. Although various prediction methods are available, distinct limitations remain such as the discordance of results between different assays and requirement of a long time and high labor and cost, restricting their wide applications in routine studies. Therefore, simpler and more rapid detection assays with high specificity and sensitivity that can be used to monitor the status of hPSCs at any time and fewer targeted markers that are more specific for a given desired cell type are urgently needed.

**Key words:** Human pluripotent stem cells; Induced pluripotent stem cells; Embryonic stem cells; Differentiation potential; Prediction; Pluripotency; Malignant potential; Embryoid bodies; Lineage-specific differentiation; Teratoma

**© The Author(s) 2019** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** To save time and costs in basic research and clinical application, it is necessary to predict the differentiation potential of human pluripotent stem cell (hPSC) lines. Multiple methods are available for pluripotency screening, lineage-specific differentiation propensity prediction, and malignancy potential detection, which can be used to select hPSCs. However, simpler and quicker methods using fewer specific targeted markers for the desired cell type are urgently required for routine work.

**Citation**: Liu LP, Zheng yw. Predicting differentiation potential of human pluripotent stem cells: Possibilities and challenges. *World J Stem Cells* 2019; 11(7): 375-382

**URL**: <https://www.wjgnet.com/1948-0210/full/v11/i7/375.htm>

**DOI**: https://dx.doi.org/10.4252/wjsc.v11.i7.375

**INTRODUCTION**

The capability of human pluripotent stem cells (hPSCs) to differentiate into any cell type has revolutionized medical research. Their widely known potential applications include the study of complex diseases, cell-based drug screening, and transplantation therapy[[1](#_ENREF_1)]. With the development of organoid technology, hPSCs also play a critical role to mimic *in vivo* tissues and organs at the three-dimensional level and provide a unique opportunity to model human organ development and study various diseases[[2](#_ENREF_2)]. In the near future, integration of multiple patient-specific hPSC-derived organoids into a dynamic four-dimensional system by organ-on-chip technology will contribute to the study of the systematic interactions among different tissues and organs in the body[[3](#_ENREF_3)]. All these applications require the selection and characterization of cell lines that reliably, efficiently, and stably differentiate into disease-relevant cell types. However, significant variation has been observed in the differentiation potential and efficiency of various human induced pluripotent stem cell (iPSC) lines[[1](#_ENREF_1),[4](#_ENREF_4),[5](#_ENREF_5)] and embryonic stem cells (ESCs)[[6-8](#_ENREF_6)], and no single cell line can uniformly differentiate into all lineages. Differences among hPSC lines mainly include DNA methylation[[9-13](#_ENREF_9)] and gene expression[[1](#_ENREF_1),[8](#_ENREF_8)], which have functional implications for both ESC and iPSC lines[[1](#_ENREF_1)]. Particularly, for iPSCs, the variations may be donor-dependent[[14](#_ENREF_14),[15](#_ENREF_15)] or original cell type-dependent[[9](#_ENREF_9)], while, in other studies, this relationship was not found[[10](#_ENREF_10),[16](#_ENREF_16)]. Moreover, the characteristics of hPSCs may differ depending on the number of passages[[17](#_ENREF_17)], culture medium components[[18](#_ENREF_18)], and feeder conditions[[19](#_ENREF_19)]. As a result, understanding the variability among different cell lines is necessary for ensuring the efficacy and safety of hPSC applications. Additionally, a long period (up to weeks or months) is typically required to complete hPSC differentiation into a specific cell type, and protocol optimization to improve differentiation efficiency is also time-consuming. Thus, these processes can be considerably accelerated if good-quality hPSC lines are selected, and their differentiation propensities into destination cell types are predicted in an early stage.

***hPSC quality control***

Given that large numbers of iPSC lines are currently and will be generated, the pluripotency of these cells must be determined before they are broadly applied. To confirm whether an iPSC line is fully reprogrammed, a teratoma assay is typically performed to reveal the differentiation capacity of hPSCs into three germ layers based on histological analysis. The pluripotency status can also be determined by detecting the expression of a set of marker genes at the molecular level[[20](#_ENREF_20)]. With the development of high-throughput sequencing techniques, numerous methods have been developed to address this issue. The PluriTest®[[21](#_ENREF_21)], a rapid test based on microarray and bioinformatics assay, provides quantitative information on hPSC quality. Two summary scores, the pluripotency score and novelty score[[22](#_ENREF_22),[23](#_ENREF_23)], which are generated from global gene expression profiles, can predict whether an hPSC line is pluripotent based on its molecular similarity to other known cell lines and exclude cells that differ substantially from normal hPSC lines. An hPSC line with a high pluripotency score and low novelty score would be regarded as having passed the PluriTest. Another assay, the “deviation scorecard”[[1](#_ENREF_1)], which combines DNA methylation and gene expression with bioinformatic comparison to an ESC reference, also provides comprehensive information and excludes problematic cell lines that should be avoided for an intended application. However, these methods can only be used to determine whether an hPSC line meets the criteria for pluripotency and do not directly assess the specific differentiation capability of the cells.

***Prediction of differentiation potential***

As described above, the teratoma assay is the most frequently used method to assess the pluripotency of hPSCs. However, it does not yield quantitative information on lineage differentiation potential[[24](#_ENREF_24)] nor provide specificity data to support the application-specific selection of the most suitable cell lines[[25](#_ENREF_25)]. Thus, the “TeratoScore” was developed[[26](#_ENREF_26)] as a quantitative and unified assessment that analyzes RNA sequencing data within heterogeneous hPSC-derived teratomas. This score weighs differences in tissue-specific expression within a teratoma and provides an estimate of the ability of an hPSC line to differentiate[[22](#_ENREF_22),[23](#_ENREF_23),[26](#_ENREF_26)] to overcome some of the limitations of histological analysis.

hPSC differentiation is a complex and multiple-step process, the beginning of which involves a particularly heterogeneous status and diverse developmental mixture. During cell fate commitment to a differentiated lineage, genes are regulated by successive transcriptional programs, and thus, the differentiation status can be determined from transcriptional profiles[[27](#_ENREF_27)]. A combination of gene expression profiling and bioinformatics assay is invaluable for predicting the trajectory of cells during differentiation. The “differentiation scale”[[27](#_ENREF_27)] based on mRNA microarray analysis can indicate the staging of differentiation and show how far the hPSCs have departed from the embryonic pluripotent state. However, this method only measures the overall capability of a cell line towards differentiation into any cell type and cannot clearly distinguish between any direction of differentiation into the three germ layers. In contrast, the “lineage scorecard” assay, which combines simple nondirected differentiation with transcript counting of 500 lineage marker genes, can detect the lineage-specific differentiation propensities of an hPSC line[[1](#_ENREF_1)]. For example, hPSC lines showing high scores for ectoderm and neural differentiation propensities are regarded as well-suited for studying neural function. This prediction has been confirmed in experiments to quantify differentiation efficiencies specific for the ectoderm germ layer. Additionally, other scores calculated based on the expression levels of a set of selected specific gene markers can predict hPSC differentiation potential in similar manners[[22](#_ENREF_22),[23](#_ENREF_23),[28](#_ENREF_28)]. These qPCR-based assays are more rapid and accessible than high-throughput methods.

According to the hPSC-derived differentiation protocols for various types of cells, embryoid bodies (EBs) are widely used[[29](#_ENREF_29)] because they mimic many aspects of cell differentiation during early embryogenesis. Because they consist of tissues containing three germ layers[[30](#_ENREF_30)], EBs can be utilized as a trigger of not only *in vitro* differentiation of hPSCs but also in assay predicting differentiation potential. For the latter purpose, EBs are induced to spontaneously differentiate under neutral conditions[[1](#_ENREF_1),[22](#_ENREF_22)] or directed into three germ layer lineages in the presence of specific growth factors[[22](#_ENREF_22),[28](#_ENREF_28)], after which gene expression profiling of EBs is conducted to assess their differentiation potential into the ectoderm, mesoderm, or endoderm lineages. In our study to predict the differentiation potential of iPSCs into melanocytes derived from the ectoderm, an EB-based assay showed that this potential could be predicted by the capability of formation and maintenance of optimal EBs under neutral conditions as well as their expression of germ layer-specific markers such as SALL3 (our unpublished data). Thus, EBs are practical tools for use in prediction assays at early stages of differentiation. In addition to EB-based protocols, monolayer differentiation[[23](#_ENREF_23),[31](#_ENREF_31)] has been adapted and shown to be applicable for evaluating endoderm and mesoderm direction; however, to predict the ectodermal direction, EB-based protocols may be more effective[[23](#_ENREF_23)].

Regardless of the detection techniques used, prediction can be achieved many days before the cells exhibit a differentiated phenotype (Table 1). For instance, the efficiency of protocols for directing differentiation to cardiac cells can be predicted at as early as day 2[[31](#_ENREF_31)], and thus can be utilized to optimize differentiation protocols, particularly for patient-specific iPSC lines by using a high-throughput screening procedure. In contrast to the above methods based on EBs or monolayer differentiation protocols, which require a couple of days before evaluation, simpler methods with limited specific markers can be used for earlier prediction using undifferentiated hPSCs. The expression level of SALL3 mRNA was used as a diagnostic marker to predict the differentiation tendency of both iPSCs and ESCs into ectodermal cells[[32](#_ENREF_32)]. hPSCs expressing the highest levels of SALL3 mRNA tend to differentiate into the most ectodermal system, while cells expressing the lowest levels of SALL3 mRNA tend to differentiate into the most mesodermal or endodermal cell types. Specifically, three genes, *FGF-1*, *RHOU*, and *TYMP*, were selected as predictors of hepatic differentiation, with low prediction scores linked to low hepatic differentiation[[33](#_ENREF_33)].

Collectively, the lineage-specific differentiation potential of hPSC lines can be predicted in an early stage using multiple assays, including the teratoma assay, different scorecards calculated by high-throughput sequencing data collected from EBs or monolayer-based differentiated hPSCs, or specific maker expression in undifferentiated hPSCs.

***Evaluation of malignancy potential***

The safety of using hPSCs in clinical application is one of the greatest concerns for both clinicians and patients[[34](#_ENREF_34)]. Currently, tumorigenicity tests are well-designed, and animal transplantation studies have been used to detect the malignancy potential of hPSC-derived cell products[[35](#_ENREF_35),[36](#_ENREF_36)]. Although residual undifferentiated cells are present among the differentiated cell population, these cells can be ablated by various techniques[[37](#_ENREF_37),[38](#_ENREF_38)]. Additionally, evaluation of hPSCs rather than their derivatives can provide safety-related information. As described above, the teratoma assay is commonly used to measure the pluripotency and differentiation potential of hPSCs[[22](#_ENREF_22),[39](#_ENREF_39)]. It is also feasible to predict the malignancy potential by detecting the immaturity of teratomas and formation of carcinoma or sarcoma in tumors derived from hPSC lines[[40](#_ENREF_40)]. Furthermore, a combination of histologic examination and “TeratoScore”, which involves computational quantification of gene expression data derived from teratoma tissue, can provide much greater detail for evaluating whether a cell line has the malignant potential[[22](#_ENREF_22),[23](#_ENREF_23)]. It is also important to examine chromosomal abnormalities by karyotype analysis[[40](#_ENREF_40),[41](#_ENREF_41)] and assess mutations in cancer-related genes[[40](#_ENREF_40)].

**LIMITATIONS AND CHALLENGES**

Collectively, multiple screening tools are available for hPSC selection with different features and prediction capabilities, and researchers can choose one or more methods according to the intended applications (Table 1 and Figure 1). However, concordance between two different prediction methods is low[[22](#_ENREF_22),[23](#_ENREF_23)], and even with the same prediction assay, distinct results may be obtained under different differentiation conditions. The lack of concordance of results makes it very difficult for researches to determine the most appropriate method for their purposes. Moreover, each prediction method has limitations, thus largely restricting its wide applications. High-throughput analysis methods such as microarray or RNA-sequencing are informative but generate excessive data, some of which are non-functional. Additionally, identifying objective genes is time- and labor-intensive as well as costly[[33](#_ENREF_33)]. The platforms used in these assays are not available to most laboratories and require customized downstream analysis, which also restricts their applications. Although teratoma formation reflects the *in vivo* differentiation capability of hPSCs and gene expression analysis can provide more definitive and quantitative information when combined with histological assessment, these methods are also very time-consuming to be feasible for validating a large number of hPSC lines[[1](#_ENREF_1)].

Because of these limitations, the methods described above are not sufficient to meet the needs of researchers in routine work. Additionally, hPSC characteristics are not stable during long-term culture, which can be affected by several factors. Further, hPSCs can vary when they are cultured using different commercial products or show different features in different laboratories, even under the same culture conditions. Therefore, a simpler and quicker detection assay with high specificity and sensitivity that can be used to monitor the status of hPSCs at any time is needed. Although most current methods are useful for lineage-direction prediction, fewer targeted markers that are more specific for a given cell type rather than all cell types are urgently needed. Moreover, EBs are ideal candidates for replacing the teratoma assay, and they should be useful for predicting differentiation potential when they are combined with modified detection methods such molecular probes, which could detect targeted markers directly.

Exceptionally, the potential prediction is not a prerequisite when iPSCs from patients with monogenic disease are utilized for disease modeling because the differentiation capability is probably interfered by gene mutation[[42](#_ENREF_42)]. However, iPSC quality control is still necessary. When using these patient-derived iPSCs for cell therapy, it is also critical to predict their differentiation potential after some special strategies such as gene editing, which can revert their defective capability.

**References**

1 **Bock C**, Kiskinis E, Verstappen G, Gu H, Boulting G, Smith ZD, Ziller M, Croft GF, Amoroso MW, Oakley DH, Gnirke A, Eggan K, Meissner A. Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. *Cell* 2011; **144**: 439-452 [PMID: 21295703 DOI: 10.1016/j.cell.2010.12.032]

2 **Lancaster MA**, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. *Science* 2014; **345**: 1247125 [PMID: 25035496 DOI: 10.1126/science.1247125]

3 **Liu C**, Oikonomopoulos A, Sayed N, Wu JC. Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond. *Development* 2018; **145** [PMID: 29519889 DOI: 10.1242/dev.156166]

4 **Koyanagi-Aoi M**, Ohnuki M, Takahashi K, Okita K, Noma H, Sawamura Y, Teramoto I, Narita M, Sato Y, Ichisaka T, Amano N, Watanabe A, Morizane A, Yamada Y, Sato T, Takahashi J, Yamanaka S. Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells. *Proc Natl Acad Sci USA* 2013; **110**: 20569-20574 [PMID: 24259714 DOI: 10.1073/pnas.1319061110]

5 **Kajiwara M**, Aoi T, Okita K, Takahashi R, Inoue H, Takayama N, Endo H, Eto K, Toguchida J, Uemoto S, Yamanaka S. Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. *Proc Natl Acad Sci USA* 2012; **109**: 12538-12543 [PMID: 22802639 DOI: 10.1073/pnas.1209979109]

6 **Di Giorgio FP**, Boulting GL, Bobrowicz S, Eggan KC. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. *Cell Stem Cell* 2008; **3**: 637-648 [PMID: 19041780 DOI: 10.1016/j.stem.2008.09.017]

7 **Osafune K**, Caron L, Borowiak M, Martinez RJ, Fitz-Gerald CS, Sato Y, Cowan CA, Chien KR, Melton DA. Marked differences in differentiation propensity among human embryonic stem cell lines. *Nat Biotechnol* 2008; **26**: 313-315 [PMID: 18278034 DOI: 10.1038/nbt1383]

8 **Sun C**, Zhang J, Zheng D, Wang J, Yang H, Zhang X. Transcriptome variations among human embryonic stem cell lines are associated with their differentiation propensity. *PLoS One* 2018; **13**: e0192625 [PMID: 29444173 DOI: 10.1371/journal.pone.0192625]

9 **Kim K**, Zhao R, Doi A, Ng K, Unternaehrer J, Cahan P, Huo H, Loh YH, Aryee MJ, Lensch MW, Li H, Collins JJ, Feinberg AP, Daley GQ. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. *Nat Biotechnol* 2011; **29**: 1117-1119 [PMID: 22119740 DOI: 10.1038/nbt.2052]

10 **Dorn I**, Klich K, Arauzo-Bravo MJ, Radstaak M, Santourlidis S, Ghanjati F, Radke TF, Psathaki OE, Hargus G, Kramer J, Einhaus M, Kim JB, Kögler G, Wernet P, Schöler HR, Schlenke P, Zaehres H. Erythroid differentiation of human induced pluripotent stem cells is independent of donor cell type of origin. *Haematologica* 2015; **100**: 32-41 [PMID: 25326431 DOI: 10.3324/haematol.2014.108068]

11 **Lister R**, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O'Malley R, Castanon R, Klugman S, Downes M, Yu R, Stewart R, Ren B, Thomson JA, Evans RM, Ecker JR. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. *Nature* 2011; **471**: 68-73 [PMID: 21289626 DOI: 10.1038/nature09798]

12 **Nishizawa M**, Chonabayashi K, Nomura M, Tanaka A, Nakamura M, Inagaki A, Nishikawa M, Takei I, Oishi A, Tanabe K, Ohnuki M, Yokota H, Koyanagi-Aoi M, Okita K, Watanabe A, Takaori-Kondo A, Yamanaka S, Yoshida Y. Epigenetic Variation between Human Induced Pluripotent Stem Cell Lines Is an Indicator of Differentiation Capacity. *Cell Stem Cell* 2016; **19**: 341-354 [PMID: 27476965 DOI: 10.1016/j.stem.2016.06.019]

13 **He W**, Kang X, Du H, Song B, Lu Z, Huang Y, Wang D, Sun X, Yu Y, Fan Y. Defining differentially methylated regions specific for the acquisition of pluripotency and maintenance in human pluripotent stem cells via microarray. *PLoS One* 2014; **9**: e108350 [PMID: 25250679 DOI: 10.1371/journal.pone.0108350]

14 **Rouhani F**, Kumasaka N, de Brito MC, Bradley A, Vallier L, Gaffney D. Genetic background drives transcriptional variation in human induced pluripotent stem cells. *PLoS Genet* 2014; **10**: e1004432 [PMID: 24901476 DOI: 10.1371/journal.pgen.1004432]

15 **Kyttälä A**, Moraghebi R, Valensisi C, Kettunen J, Andrus C, Pasumarthy KK, Nakanishi M, Nishimura K, Ohtaka M, Weltner J, Van Handel B, Parkkonen O, Sinisalo J, Jalanko A, Hawkins RD, Woods NB, Otonkoski T, Trokovic R. Genetic Variability Overrides the Impact of Parental Cell Type and Determines iPSC Differentiation Potential. *Stem Cell Reports* 2016; **6**: 200-212 [PMID: 26777058 DOI: 10.1016/j.stemcr.2015.12.009]

16 **Philonenko ES**, Shutova MV, Khomyakova EA, Vassina EM, Lebedeva OS, Kiselev SL, Lagarkova MA. Differentiation of Human Pluripotent Stem Cells into Mesodermal and Ectodermal Derivatives Is Independent of the Type of Isogenic Reprogrammed Somatic Cells. *Acta Naturae* 2017; **9**: 68-74 [PMID: 28461976 DOI: 10.32607/20758251-2017-9-1-68-74]

17 **Enver T**, Soneji S, Joshi C, Brown J, Iborra F, Orntoft T, Thykjaer T, Maltby E, Smith K, Abu Dawud R, Jones M, Matin M, Gokhale P, Draper J, Andrews PW. Cellular differentiation hierarchies in normal and culture-adapted human embryonic stem cells. *Hum Mol Genet* 2005; **14**: 3129-3140 [PMID: 16159889 DOI: 10.1093/hmg/ddi345]

18 **Nishihara K**, Shiga T, Nakamura E, Akiyama T, Sasaki T, Suzuki S, Ko MSH, Tada N, Okano H, Akamatsu W. Induced Pluripotent Stem Cells Reprogrammed with Three Inhibitors Show Accelerated Differentiation Potentials with High Levels of 2-Cell Stage Marker Expression. *Stem Cell Reports* 2019; **12**: 305-318 [PMID: 30713040 DOI: 10.1016/j.stemcr.2018.12.018]

19 **Draper JS**, Smith K, Gokhale P, Moore HD, Maltby E, Johnson J, Meisner L, Zwaka TP, Thomson JA, Andrews PW. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. *Nat Biotechnol* 2004; **22**: 53-54 [PMID: 14661028 DOI: 10.1038/nbt922]

20 **International Stem Cell Initiative.**, Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, Beighton G, Bello PA, Benvenisty N, Berry LS, Bevan S, Blum B, Brooking J, Chen KG, Choo AB, Churchill GA, Corbel M, Damjanov I, Draper JS, Dvorak P, Emanuelsson K, Fleck RA, Ford A, Gertow K, Gertsenstein M, Gokhale PJ, Hamilton RS, Hampl A, Healy LE, Hovatta O, Hyllner J, Imreh MP, Itskovitz-Eldor J, Jackson J, Johnson JL, Jones M, Kee K, King BL, Knowles BB, Lako M, Lebrin F, Mallon BS, Manning D, Mayshar Y, McKay RD, Michalska AE, Mikkola M, Mileikovsky M, Minger SL, Moore HD, Mummery CL, Nagy A, Nakatsuji N, O'Brien CM, Oh SK, Olsson C, Otonkoski T, Park KY, Passier R, Patel H, Patel M, Pedersen R, Pera MF, Piekarczyk MS, Pera RA, Reubinoff BE, Robins AJ, Rossant J, Rugg-Gunn P, Schulz TC, Semb H, Sherrer ES, Siemen H, Stacey GN, Stojkovic M, Suemori H, Szatkiewicz J, Turetsky T, Tuuri T, van den Brink S, Vintersten K, Vuoristo S, Ward D, Weaver TA, Young LA, Zhang W. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. *Nat Biotechnol* 2007; **25**: 803-816 [PMID: 17572666 DOI: 10.1038/nbt1318]

21 **Müller FJ**, Schuldt BM, Williams R, Mason D, Altun G, Papapetrou EP, Danner S, Goldmann JE, Herbst A, Schmidt NO, Aldenhoff JB, Laurent LC, Loring JF. A bioinformatic assay for pluripotency in human cells. *Nat Methods* 2011; **8**: 315-317 [PMID: 21378979 DOI: 10.1038/nmeth.1580]

22 **International Stem Cell Initiative.**. Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells. *Nat Commun* 2018; **9**: 1925 [PMID: 29765017 DOI: 10.1038/s41467-018-04011-3]

23 **Bouma MJ**, van Iterson M, Janssen B, Mummery CL, Salvatori DCF, Freund C. Differentiation-Defective Human Induced Pluripotent Stem Cells Reveal Strengths and Limitations of the Teratoma Assay and In Vitro Pluripotency Assays. *Stem Cell Reports* 2017; **8**: 1340-1353 [PMID: 28494940 DOI: 10.1016/j.stemcr.2017.03.009]

24 **Andrews PW**, Baker D, Benvinisty N, Miranda B, Bruce K, Brüstle O, Choi M, Choi YM, Crook JM, de Sousa PA, Dvorak P, Freund C, Firpo M, Furue MK, Gokhale P, Ha HY, Han E, Haupt S, Healy L, Hei DJ, Hovatta O, Hunt C, Hwang SM, Inamdar MS, Isasi RM, Jaconi M, Jekerle V, Kamthorn P, Kibbey MC, Knezevic I, Knowles BB, Koo SK, Laabi Y, Leopoldo L, Liu P, Lomax GP, Loring JF, Ludwig TE, Montgomery K, Mummery C, Nagy A, Nakamura Y, Nakatsuji N, Oh S, Oh SK, Otonkoski T, Pera M, Peschanski M, Pranke P, Rajala KM, Rao M, Ruttachuk R, Reubinoff B, Ricco L, Rooke H, Sipp D, Stacey GN, Suemori H, Takahashi TA, Takada K, Talib S, Tannenbaum S, Yuan BZ, Zeng F, Zhou Q. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). *Regen Med* 2015; **10**: 1-44 [PMID: 25675265 DOI: 10.2217/rme.14.93]

25 **Boulting GL**, Kiskinis E, Croft GF, Amoroso MW, Oakley DH, Wainger BJ, Williams DJ, Kahler DJ, Yamaki M, Davidow L, Rodolfa CT, Dimos JT, Mikkilineni S, MacDermott AB, Woolf CJ, Henderson CE, Wichterle H, Eggan K. A functionally characterized test set of human induced pluripotent stem cells. *Nat Biotechnol* 2011; **29**: 279-286 [PMID: 21293464 DOI: 10.1038/nbt.1783]

26 **Avior Y**, Biancotti JC, Benvenisty N. TeratoScore: Assessing the Differentiation Potential of Human Pluripotent Stem Cells by Quantitative Expression Analysis of Teratomas. *Stem Cell Reports* 2015; **4**: 967-974 [PMID: 26070610 DOI: 10.1016/j.stemcr.2015.05.006]

27 **Zagar L**, Mulas F, Garagna S, Zuccotti M, Bellazzi R, Zupan B. Stage prediction of embryonic stem cell differentiation from genome-wide expression data. *Bioinformatics* 2011; **27**: 2546-2553 [PMID: 21765096 DOI: 10.1093/bioinformatics/btr422]

28 **Tsankov AM**, Akopian V, Pop R, Chetty S, Gifford CA, Daheron L, Tsankova NM, Meissner A. A qPCR ScoreCard quantifies the differentiation potential of human pluripotent stem cells. *Nat Biotechnol* 2015; **33**: 1182-1192 [PMID: 26501952 DOI: 10.1038/nbt.3387]

29 **Liu LP**, Li YM, Guo NN, Li S, Ma X, Zhang YX, Gao Y, Huang JL, Zheng DX, Wang LY, Xu H, Hui L, Zheng YW. Therapeutic Potential of Patient iPSC-Derived iMelanocytes in Autologous Transplantation. *Cell Rep* 2019; **27**: 455-466.e5 [PMID: 30970249 DOI: 10.1016/j.celrep.2019.03.046]

30 **Kurosawa H**. Methods for inducing embryoid body formation: in vitro differentiation system of embryonic stem cells. *J Biosci Bioeng* 2007; **103**: 389-398 [PMID: 17609152 DOI: 10.1263/jbb.103.389]

31 **Bargaje R**, Trachana K, Shelton MN, McGinnis CS, Zhou JX, Chadick C, Cook S, Cavanaugh C, Huang S, Hood L. Cell population structure prior to bifurcation predicts efficiency of directed differentiation in human induced pluripotent cells. *Proc Natl Acad Sci USA* 2017; **114**: 2271-2276 [PMID: 28167799 DOI: 10.1073/pnas.1621412114]

32 **Kuroda T,** Yasuda S, Sato T, inventors; Evaluation Method of Differentiation Tendency among Undifferentiated Cells, Sall3 Mrna as Evaluation Marker for Differentiation Tendency, and Method of Controlling Differentiation Ability of Undifferentiated Cells. Japan Patent. JP2016073791A 2016 April 1

33 **Yanagihara K**, Liu Y, Kanie K, Takayama K, Kokunugi M, Hirata M, Fukuda T, Suga M, Nikawa H, Mizuguchi H, Kato R, Furue MK. Prediction of Differentiation Tendency Toward Hepatocytes from Gene Expression in Undifferentiated Human Pluripotent Stem Cells. *Stem Cells Dev* 2016; **25**: 1884-1897 [PMID: 27733097 DOI: 10.1089/scd.2016.0099]

34 **Seki T**, Fukuda K. Methods of induced pluripotent stem cells for clinical application. *World J Stem Cells* 2015; **7**: 116-125 [PMID: 25621111 DOI: 10.4252/wjsc.v7.i1.116]

35 **Kawamata S**, Kanemura H, Sakai N, Takahashi M, Go MJ. Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products. *J Clin Med* 2015; **4**: 159-171 [PMID: 26237025 DOI: 10.3390/jcm4010159]

36 **Kanemura H**, Go MJ, Shikamura M, Nishishita N, Sakai N, Kamao H, Mandai M, Morinaga C, Takahashi M, Kawamata S. Tumorigenicity studies of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration. *PLoS One* 2014; **9**: e85336 [PMID: 24454843 DOI: 10.1371/journal.pone.0085336]

37 **Itakura G**, Kawabata S, Ando M, Nishiyama Y, Sugai K, Ozaki M, Iida T, Ookubo T, Kojima K, Kashiwagi R, Yasutake K, Nakauchi H, Miyoshi H, Nagoshi N, Kohyama J, Iwanami A, Matsumoto M, Nakamura M, Okano H. Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives. *Stem Cell Reports* 2017; **8**: 673-684 [PMID: 28262544 DOI: 10.1016/j.stemcr.2017.02.003]

38 **Zarogoulidis P**, Darwiche K, Sakkas A, Yarmus L, Huang H, Li Q, Freitag L, Zarogoulidis K, Malecki M. Suicide Gene Therapy for Cancer - Current Strategies. *J Genet Syndr Gene Ther* 2013; **4** [PMID: 24294541 DOI: 10.4172/2157-7412.1000139]

39 **Bulic-Jakus F**, Katusic Bojanac A, Juric-Lekic G, Vlahovic M, Sincic N. Teratoma: from spontaneous tumors to the pluripotency/malignancy assay. *Wiley Interdiscip Rev Dev Biol* 2016; **5**: 186-209 [PMID: 26698368 DOI: 10.1002/wdev.219]

40 **Yasuda S**, Kusakawa S, Kuroda T, Miura T, Tano K, Takada N, Matsuyama S, Matsuyama A, Nasu M, Umezawa A, Hayakawa T, Tsutsumi H, Sato Y. Tumorigenicity-associated characteristics of human iPS cell lines. *PLoS One* 2018; **13**: e0205022 [PMID: 30286143 DOI: 10.1371/journal.pone.0205022]

41 **International Stem Cell Initiative.**, Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, Beil S, Benvenisty N, Ben-Yosef D, Biancotti JC, Bosman A, Brena RM, Brison D, Caisander G, Camarasa MV, Chen J, Chiao E, Choi YM, Choo AB, Collins D, Colman A, Crook JM, Daley GQ, Dalton A, De Sousa PA, Denning C, Downie J, Dvorak P, Montgomery KD, Feki A, Ford A, Fox V, Fraga AM, Frumkin T, Ge L, Gokhale PJ, Golan-Lev T, Gourabi H, Gropp M, Lu G, Hampl A, Harron K, Healy L, Herath W, Holm F, Hovatta O, Hyllner J, Inamdar MS, Irwanto AK, Ishii T, Jaconi M, Jin Y, Kimber S, Kiselev S, Knowles BB, Kopper O, Kukharenko V, Kuliev A, Lagarkova MA, Laird PW, Lako M, Laslett AL, Lavon N, Lee DR, Lee JE, Li C, Lim LS, Ludwig TE, Ma Y, Maltby E, Mateizel I, Mayshar Y, Mileikovsky M, Minger SL, Miyazaki T, Moon SY, Moore H, Mummery C, Nagy A, Nakatsuji N, Narwani K, Oh SK, Oh SK, Olson C, Otonkoski T, Pan F, Park IH, Pells S, Pera MF, Pereira LV, Qi O, Raj GS, Reubinoff B, Robins A, Robson P, Rossant J, Salekdeh GH, Schulz TC, Sermon K, Sheik Mohamed J, Shen H, Sherrer E, Sidhu K, Sivarajah S, Skottman H, Spits C, Stacey GN, Strehl R, Strelchenko N, Suemori H, Sun B, Suuronen R, Takahashi K, Tuuri T, Venu P, Verlinsky Y, Ward-van Oostwaard D, Weisenberger DJ, Wu Y, Yamanaka S, Young L, Zhou Q. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. *Nat Biotechnol* 2011; **29**: 1132-1144 [PMID: 22119741 DOI: 10.1038/nbt.2051]

42 **Shalom-Feuerstein R**, Serror L, Aberdam E, Müller FJ, van Bokhoven H, Wiman KG, Zhou H, Aberdam D, Petit I. Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET. *Proc Natl Acad Sci USA* 2013; **110**: 2152-2156 [PMID: 23355677 DOI: 10.1073/pnas.1201753109]

43 **Yamamoto T**, Takenaka C, Yoda Y, Oshima Y, Kagawa K, Miyajima H, Sasaki T, Kawamata S. Differentiation potential of Pluripotent Stem Cells correlates to the level of CHD7. *Sci Rep* 2018; **8**: 241 [PMID: 29321579 DOI: 10.1038/s41598-017-18439-y]

44 **Siller R**, Naumovska E, Mathapati S, Lycke M, Greenhough S, Sullivan GJ. Development of a rapid screen for the endodermal differentiation potential of human pluripotent stem cell lines. *Sci Rep* 2016; **6**: 37178 [PMID: 27872482 DOI: 10.1038/srep37178]

**P-Reviewer:** Andrukhov O, Binetruy B, Huang YC, Politi LE, Wang H, Zeng L **S-Editor:** Ma YJ **L-Editor:** Wang TQ **E-Editor:** Ma YJ

**Specialty type:** Cell and tissue engineering

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B, B, B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Schematic flow diagram of quality control of human pluripotent stem cells.** hPSCs: human pluripotent stem cells.

**Table 1 Methods for evaluating human pluripotent stem cell lines for pluripotency, differentiation potential, and malignant potential**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Aim** | **Techniques** | **Targets** | **Cell treatment** | **Timepoint****detection** | **Ref.** |
| Pluripotency | DNA methylation sequencing and microarray | Deviation scorecard: the cell line-specific number of outliers relative to the human ES cell reference | N/A | N/A | [[1](#_ENREF_1)] |
| Microarray | PluriTest: pluripotency score (refers to gene expression profiles of a large collection of human PSCs) and novelty score (refers to gene expression patterns not typically associated with human PSCs) | N/A | N/A | [[21-23](#_ENREF_21)] |
| qPCR | Level of CHD7 | N/A | N/A | [[43](#_ENREF_43)] |
| Differentiation potential | Microarray | Differentiation scale: a subset of the 1000 most informative genes | W/O | At any time of differentiation | [[27](#_ENREF_27)] |
| Microarray | Lineage scorecard: 500 lineage marker genes to monitor cell state, pluripotency, and differentiation | Nondirected EB differentiation  | At 16 d of differentiation | [[1](#_ENREF_1)] |
| qPCR | Lineage scorecard: 15 selected marker genes per lineage  | Nondirected and directed differentiation into three germ lineages | [[22](#_ENREF_22)] |
| qPCR | hPSC ScoreCard: 9 self-renewal genes and 70 genes representing specific lineages | Monolayer or EB protocol differentiation into three germ lineages | At 5 or 9 d | [[23](#_ENREF_23)] |
| Single-cell qPCR | 96 developmental genes; a transcriptional circuit (HAND1-SOX17) and phenotypic readout (cKIT distribution) | Cardiomyocyte differentiation | On day 2 | [[31](#_ENREF_31)] |
| qPCR | Improved scorecard: 96 specific gene markers | Directed EB differentiation into three germ lineages | At 12 d of differentiation. | [[28](#_ENREF_28)] |
| Microarray or RNA-sequencing | TeratoScore: 100 tissue-specific genes representing the three embryonic germ layers and extra- embryonic membranes | Xenograft teratoma formation | A suitable growth period | [[22](#_ENREF_22),[23](#_ENREF_23),[26](#_ENREF_26)] |
| Morphology | Definitive endoderm morphology production | Treated with small molecules | 48 h after induction | [[44](#_ENREF_44)] |
| qPCR | SALL3 for ectodermal differentiation | N/A | N/A | [[32](#_ENREF_32)] |
| PCR array | Prediction scores for hepatic differentiation based on the expression of the three genes *FGF-1*, *RHOU*, and *TYMP* | N/A | N/A | [[33](#_ENREF_33)] |
| Malignantpotential | Histology, qPCR, and microarray | TeratoScore: 10 undifferentiated hPSC markers; embryonal carcinoma-like cells with yolk sac elements; undifferentiated hPSC marker and malignancy marker expression | Xenograft teratoma formation | Suitable growth period | [[22](#_ENREF_22)]  |
| TeratoScore: 100 tissue-specific genes; embryonal carcinoma-like cells; undifferentiated hPSC marker and malignancy marker expression | [[23](#_ENREF_23)] |
| Histology, microarray, karyotype analysis, and whole exome sequencing | Formation of immature teratomas, carcinoma and sarcoma; mutation of cancer-related genes; chromosomal abnormalities | Xenograft teratoma formation; N/A | Suitable growth period; N/A | [40] |

hPSCs: human pluripotent stem cells; N/A: Not available.